Autonomix Medical Inc. announced preclinical results for its neural sensing platform used in renal denervation, alongside the receipt of U.S. Patent No. 12,471,776 covering proprietary neuromodulation technology. The preclinical study demonstrated that the platform could detect renal neural activity and guide targeted ablation, addressing a key challenge in treating resistant hypertension. The company plans to advance into further preclinical and clinical studies. Shares of AMIX closed Friday at $2.92, down 16.57%, though they rose 3.02% in afterhours trading to $3.42.
Autonomix Medical, Inc. Common StockPreclinical data and patent are positive for technology, but stock fell 16% on the news, with afterhours recovery suggesting mixed market reaction.